Leucovorin, fluorouracil, and oxaliplatin (FOLFOX 6 and 7) regimens for colorectal cancer

Hospital Pharmacy

Volumn 40, Issue 8, 2005, Pages

  Waddell, J Aubrey ^b   Solimando, Dominic A ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; APREPITANT; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; FLUOROURACIL; FOLINIC ACID; GLUCONATE CALCIUM; GRANISETRON; LOPERAMIDE; MAGNESIUM SULFATE; METOCLOPRAMIDE; ONDANSETRON; OXALIPLATIN; PALONOSETRON; PROCHLORPERAZINE; PROMETHAZINE; RECOMBINANT COLONY STIMULATING FACTOR;

ALOPECIA; ANEMIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SYNTHESIS; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LUNG EMBOLISM; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PRESCRIPTION; REVIEW; SENSORY NEUROPATHY; SKIN TOXICITY; STOMACH MUCOSA; STOMATITIS; THROMBOCYTOPENIA;

EID: 24744462076     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870504000805     Document Type: Review

References (27)

1. National Comprehensive Cancer Network. NCCN colon cancer practice guidelines v.3.2005. Available at:www.nccn.org. Accessed on June 1, 2005.
2. Goldstein D, Mitchell P, Michael M, et al. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer. 2005;92:832-837.
3. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
4. Ducreux M, Adenis A, Bennouna J, et al. Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): findings from an interim safety analysis. Abstract 3596 presented at: 2005 ASCO Annual Meeting; May 14-17, 2005. Orlando, Fl.
5. Maindrault-Goebel F, Louvet C, Andre T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 6). Eur J Cancer. 1999; 35:1338-1342.
6. De Gramont A, Cervantes A, Andre T, et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. J Clin Oncol. 2005;22(suppl 3525):1209-1214.
7. Taieb J, Artru P, Paye F, et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 2005;23:502-509.
8. de Gramont A, Tournigand C, Louvet C, et al. Oxaliplatin, folinic acid, and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD. Rev Med Interne. 1997;18:769-775.
9. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with and without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
10. National Comprehensive Cancer Network. NCCN antiemesis practice guidelines v. 1.2005. Available at: www.nccn.org. Accessed on June 1, 2005.
11. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-109.
12. Weiss RB. Hypersensitivity reactions. Semin Oncol. 1992;19:458-477.
13. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
14. Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003;89:477-481.
15. Qureshi KM, Leichman C, Berdzik J, et al. Incidence of hypersensitivity reactions to oxaliplatin (OXP) at Roswell Park Cancer Institute (RPCI) and protocol for desensitization. Proc Am Soc Clin Oncol. 2003; 22:789 (abstract 3173).
16. Dold F, Hoey D, Carberry M, et al. Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin. Proc Am Soc Clin Oncol. 2002 (abstract 1478).
17. Lyman GH, Balducci L. A cost analysis of hematopoietic colony-stimulating factors. Oncology. 1995;9(suppl 11):85-91.
18. Lyman GH. Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol. 2003; 30(suppl 13):10-17.
19. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 2000;18:3558-3585.
20. Kretzschmar A, Thuss-Patience PC, Pink D, et al. Extravasations (E) of oxaliplatin (O). Proc Am Soc Clin Oncol. 2002 (abstract 2900).
21. Benson AB, Ajani JA, Catalane RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22:2918-2926.
22. Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002;29(suppl 15):21-33.
23. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10:4055-4061.
24. Takimoto CH, Remick SC, Sharma S, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute organ dysfunction working group study. J Clin Oncol. 2003;21:2664-2672.
25. Doroshow JH, Synold TW, Gandara D, et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol. 2003;30(suppl 15):14-19.
26. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinsuoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460-466.
27. King PD, Perry MC. Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am. 1995; 24:969-989.